ProMetic Life Sciences Inc. (TSE:PLI) received a C$4.50 price objective from investment analysts at TD Securities in a report issued on Wednesday. The firm presently has a a “speculative buy” rating on the stock. TD Securities’ price target suggests a potential upside of 63.64% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. CIBC reduced their price objective on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Bloom Burton reissued a “hold” rating on shares of ProMetic Life Sciences in a research report on Thursday, October 13th. Royal Bank Of Canada reissued an “outperform” rating and issued a C$4.70 price objective on shares of ProMetic Life Sciences in a research report on Wednesday. Finally, Scotiabank reissued an “outperform” rating and issued a C$5.00 price objective on shares of ProMetic Life Sciences in a research report on Thursday, October 27th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) traded down 1.82% during trading on Wednesday, hitting $2.70. 2,282,439 shares of the stock traded hands. ProMetic Life Sciences has a one year low of $1.88 and a one year high of $3.62. The company has a 50-day moving average price of $2.90 and a 200 day moving average price of $2.94. The stock’s market cap is $1.63 billion.

About ProMetic Life Sciences

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.